Omeros Sells Zaltenibart Rights to Novo Nordisk for $240 Million Upfront
Omeros Corporation has sold the rights to its clinical-stage MASP-3 inhibitor, zaltenibart, to Novo Nordisk for $240 million upfront. Omeros is also eligible for up to $2.1 billion in milestone payments and royalties. Novo Nordisk now holds global rights to zaltenibart, while Omeros retains certain MASP-3 small-molecule program rights.
Omeros Corporation announced the closing of an asset sale and licensing agreement with Novo Nordisk for its clinical-stage MASP-3 inhibitor, zaltenibart (formerly OMS906). Omeros received $240 million in upfront cash and is eligible for up to $2.1 billion in potential milestone payments and royalties. Novo Nordisk now holds global rights to zaltenibart and related assets, while Omeros retains certain MASP-3 small-molecule program rights. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201875667) on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
